It doesn't take much to boost your passive income stream with these top dividend-paying stocks.Would you like to widen the stream of passive income you can expect each year? Managing rental property is an option, but most retirees find this method less passive than they would like it to be.Investors who are attracted to truly passive income generation may want to consider AT&T (T 1.60%), PenantPark Floating Rate Capital (PFLT -0.26%), and Pfizer (PFE). They offer an average yield of 7.6% at recent prices, s ...

Pfizer (PFE) closed at $27.41 in the latest trading session, marking a +1.59% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.25%. Elsewhere, the Dow gained 0.15%, while the tech-heavy Nasdaq added 0.03%.Prior to today's trading, shares of the drugmaker had lost 5.43% over the past month. This has lagged the Medical sector's gain of 0.11% and the S&P 500's gain of 3.34% in that time.The investment community will be closely monitoring the performance of Pfizer in its f ...

Kansas on Monday sued Pfizer, accusing the company of misleading the public about its COVID-19 vaccine by hiding risks while making false claims about its effectiveness.In a lawsuit filed in the District Court of Thomas County, the state said the New York-based drugmaker’s alleged false statements violated the Kansas Consumer Protection Act. It is seeking unspecified money damages.“Pfizer made multiple misleading statements to deceive the public about its vaccine at a time when Americans needed the truth,” ...

Loading...Loading...BioNTech SE’s BNTX partner MediLink Therapeutics (Suzhou) Co., Ltd says the FDA has placed a partial clinical hold on the Phase 1 trial.The MediLink-sponsored trial evaluates the early-stage antibody-drug conjugate product candidate BNT326/YL202 as a later-line treatment in heavily pre-treated patients with advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer or HR+/HER2-negative breast cancer.Also Read: What’s Going With BioNTech Stock On Monday?The ...

Loading...Loading...The state of Kansas has reportedly filed a lawsuit against pharmaceutical giant Pfizer, Inc. PFE, accusing the company of violating consumer protection laws related to its COVID-19 vaccine.Kansas Attorney General Kris Kobach argues that Pfizer marketed the vaccine as “safe” despite allegedly knowing it was linked to serious adverse events.Citing the 69-page lawsuit submitted to the District Court of Thomas County, Fox Business highlights that Pfizer misled the public by claiming its COVI ...

NEW YORK, NEW YORK - MAY 22: Dr. Albert Bourla, Chairman and CEO, Pfizer speaks onstage during The ... [+] Wall Street Journal's 2024 The Future Of Everything Festival at Spring Studios on May 22, 2024 in New York City. (Photo by Dia Dipasupil/Getty Images)Getty ImagesPfizer stock (NYSE: PFE) currently trades at $28 per share, 55% below its peak level of $61 seen in December 2021. In contrast, Merck stock is up 36% over this period. PFE stock was trading at $52 in early June 2022, just before the Fed starte ...

It's no secret that the last year has been punishing.Are Pfizer's (PFE -0.04%) best days behind it? If the stock's critics are to be believed, the answer is an emphatic "yes, obviously," with issues like its recent stint of unprofitability and a beaten-down top line being the primary pieces of supporting evidence.But even the best companies can sometimes have a few quarters of difficulty, and investors should hesitate before counting this stock out. Let's analyze the arguments on each side and reach an acti ...

Pfizer (PFE) announced that a phase III study on its mini-dystrophin gene therapy fordadistrogene movaparvovec for treating Duchenne muscular dystrophy (“DMD”) failed to meet the primary endpoint as well as key secondary endpoints.The global phase III study, CIFFREO is investigating fordadistrogene movaparvovec in patients 4-8 years of age with DMD. A progressive and degenerative disorder, DMD leads to weakness and wasting away of the body’s muscles due to disruption of dystrophin production. The disease us ...

no_limit_picturesA difficult period for Pfizer (NYSE:PFE) might be coming to an end. The series of setbacks, such as the failures of the obesity pipeline during 2023, and the commercial underperformance that led to expectations reset with a “kitchen sink” guidance for 2024, are now behind us, and the COVID-19 franchise-led declines in revenues are finally in the rearview mirror. My share price bottom call from last year was premature, but I believe better times are ahead and that a return to growth led ...

Pfizer (PFE) closed the latest trading day at $27.66, indicating a -1.32% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.85%. Meanwhile, the Dow lost 0.09%, and the Nasdaq, a tech-heavy index, added 1.53%.Coming into today, shares of the drugmaker had lost 1.23% in the past month. In that same time, the Medical sector gained 2.46%, while the S&P 500 gained 3.11%.The upcoming earnings release of Pfizer will be of great interest to investors. The comp ...